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In a recent series of experiments, we observed that epidermal 
Langerhans cells (LC) of healthy, non-atopic individuals 
have the capacity of specifically binding monomeric serum or 
myeloma IgE. IgE-binding to LC could neither be prevented 
by pre-incubation of the cryostat sections with monoclonal 
antibodies (MoAb) against either FceRII/CD23 or FcyRIII 
CD32 nor by the addition of excess amounts of lactose, but 
could be entirely abrogated by pre-incubation with the anti-
FceRI MoAb 15-1. A direct testing of the anti-FceRI MoAb 
15-1 and 19-1 on cryostat sections in an indirect immuno-
double-labeling technique showed that, in contrast to eight 
different anti-FceRII/CD23 MoAb, these MoAb react with 
the majority of CDla-bearing-epidermal cells. At an ultra-
B ruynzeel-Koomen and co-workers [1,2] were the first to describe that epidermal Langerhans cells (LC) in lesional and non-Iesional skin of atopic dermatitis (AD) patients have IgE-binding capacity. Further-more, it was shown that, after acid-stripping of cell-
bound IgE, the anti-igE reactivity of LC can be restored by incuba-
tion of tissue substrates with native, but not with heated, autologous 
IgE-rich serum [1]. In view of the heat lability of the Fce fragment, 
this observation led to the concept that IgE binds to LC via its Fce 
fragment [1]. 
Because exposure of LC-enriched epidermal cells from non-ato-
pics to IL-4 and/or IFN-y leads to the surface expression of anti-
FceRIl/CD23-reactive moieties on LC [3], it was originally 
thought that LC in AD skin bind IgE via FceRII/CD23 induced by 
cytokines present in the AD skin microenvironment. Evidence con-
tradicting this concept came from the recent finding that IgE+ LC 
are also detectable in other diseases, provided that the serum IgE 
level exceeded 100 kU /1 [4]. It was therefore reasonable to assume 
that the presence ofIgE-binding sites on human epidermal LC is not 
a consequence of the respective disease process, but rather represents 
a constitutive property of these cells. 
In a first series of experiments, we addressed this issue by exposing 
normal-appearing skin sections of non-atopic individuals to various 
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structural level, 15-1 immunogold-Iabeling in the epidermis 
was confined to the surface of cells exhibiting Birbeck gran-
ules. In further experiments, we were able to amplify by 
polymerase chain reaction (PCR) technology transcripts for 
the lX, p, and y chains of FceRI from LC-enriched epidermal 
cells and dermal cells, but not from LC-depleted epidermal 
cells. Transcripts for the mast cell enzyme tryptase were ex-
clusively found in dermal cell- derived RNA preparations, 
thus excluding a contamination of the LC-enriched epider-
mal cell preparations by dermal mast cells. Collectively, these 
data show that epidermal LC, but no other epidermal cells, 
express FceRI molecules.] Invest Dermatol99:30S - 32S, 1992 
IgE preparations and then visualizing cell-bound IgE in an indirect 
immunoperoxidase method. We found that this immunolabeling 
procedure regularly revealed anti-IgE reactive cells in both the epi-
dermis and dermis. IgE+ epidermal cells were dendritic in shape, 
located at a suprabasal position, displayed uniform anti-CDla reac-
tivity, and, thus, qualified as LC [5] (Fig lA,B). In analogy, flow-
cytometric studies revealed that CDla+ cells were the only IgE-
binding epidermal cells and, conversely, that most of CDla+ 
epidermal cells (i.e., LC) are capable ofIgE binding. In the dermis, a 
portion of IgE+ cells reacted with the mast-cell label fluorescein 
isothiocyanate (FITC)/avidin (Fig le,D). Other IgE+ cells were 
FITC/avidin- and were preferentially located around the dermal 
microvasculature. One may speculate that these cells belong to the 
ill-defined population of dermal dendrocytes [5] . 
In a second series of experiments, our goal was to define the 
IgE-binding structure on epidermal LC by pre-incubation of the 
tissue with reagents capable of blocking the IgE-binding sites of the 
known IgE-binding structures [5]. i.e., 1} the tetrameric FceRI con-
sisting of one a-, one p-, and two y-chains, which binds homolo-
gous and heterologous monomeric IgE with high affinity [6,7]; 2} 
FceRll/CD23, a single-chain molecule, which binds IgE with an 
approximately 100-times lower affinity than FceRI [8,9]; 3) the 
e-binding protein (eBP) , a galactoside-specific lectin [10]; and 4) the 
single-chained FcyRII/CD32, which binds monomeric IgG with 
very low affinity [7], and which, in the murine system, is capable of 
binding IgE-immune complexes [10] . 
We found that IgE-binding to LC could not be prevented by 
p~e-incubation of cryostat se.ctions with reagents known to block Ig 
bmdmg to FceRIl/CD23 (1.e., MoAb MHM6), to eBP (i.e., lac-
tose), and to FcyRll (i.e., MoAb IV-3), but could be entirely abro-
gated by pre-incubation with the anti-FceRIa MoAb 15-1 [5] . A 
direct testing of the anti-FceRIa MoAb 15-1 and 19-1 on cryostat 
sections in an indirect immunodollble-labeling technique showed 
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Figure 1. Den~onstration of.lgE bound to LC and mast cells in normal human skin. After pre-incubation with IgE~ tissue sections were reacted with anti-.I~E 
MoAb in an indirect (rhodamme) nnmunofluorescence procedure (A, C, arrows) and counterstamed with either antl-CDla! FITC (B, arrows) or FITC!avldm 
(D, arrows). Dotted litle, dermal-epidermal junction; e, epidermis; d, dermis. Magnification X 400. 
that, in contrast to a panel of different anti-FcERII/CD23 MoAb, 
these MoAb react with the majority of CD la-bearing epidermal 
cells (i.e., Le). At an ultrastructural level, 15-1 immunogold-labe-
ling was confined to the surface of cells exhibiting Birbeck granules. 
In the dermis, FCERI+ cells were frequently clustered around the 
dermal microvascu lature and included FITC/avidin+ as well as 
FlTC/avidin- cells. 
To determine whether FCERI in LC have the same molecular 
con1iguration as in mast cells, we searched for the respective gene 
transcripts in LC by PCR technology. In four independent experi-
ments we were able to amplify transcripts of comparable intensity 
from LC-enriched epidermal cells for the (X- and y-chains but de-
tected only trace amounts of p-chain transcripts. This low level of 
FCERI p-chain mRNA in LC-enriched epidermal cell suspensions 
may simply be attributable to differences in amplification efficiency. 
Alternatively, this finding is also compatible with the possibility 
that the Fc receptor for monomeric IgE on LC occurs in two config-
urations: one form identical to that found on mast cells and baso-
phils and the other form consisting only of (X- and y-chains, a heter-
odimeric configuration that has been shown, at least in transfectants 
to suffice for surface expression of high-affinity IgE-binding sites 
[11]. 
Although a role for FCERI in the IgE-binding to LC in AD skin 
has yet to be shown, one may speculate that in AD skin antigeneti-
cally cross-linked IgE on LC may stimulate events in these cells 
similar to those occurring in mast cells resulting in the production 
and release of soluble mediators [12] and cytokines [13-15]. The 
recent observation that IgE-bearing LC derived from AD skin are 
superior to IgE- LC in their capacity to present house dust antigen 
to sensitized T cells [16] indicates that FCERI on LC may also playa 
crucial role in the uptake and/or processing of allergens by these 
cells. Should further studies establish and substantiate the role of 
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this receptor in diseased skin, the development of a topical agent 
capable of interfering with FceR! function may be a useful strategy 
for the therapy of allergic skin diseases. 
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